Anzeige
Mehr »
Login
Freitag, 25.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3E2GR | ISIN: US4510337086 | Ticker-Symbol: 0JV0
NASDAQ
24.04.25
21:54 Uhr
0,832 US-Dollar
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
IBIO INC Chart 1 Jahr
5-Tage-Chart
IBIO INC 5-Tage-Chart

Aktuelle News zur IBIO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiiBio, Inc. - 8-K, Current Report12
DiiBio, Inc.: iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio7
IBIO Aktie jetzt für 0€ handeln
07.04.iBio reports promising data on obesity treatment antibody8
07.04.iBio, Inc.: iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline125Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days Additional interim in vivo...
► Artikel lesen
07.04.iBio, Inc. - 8-K, Current Report2
03.03.iBio, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities8
03.03.iBio, Inc. - 8-A12B, Registration of securities3
19.02.iBio, Inc. - 8-K, Current Report2
10.02.iBio GAAP EPS of -$0.484
10.02.iBio, Inc.: iBio Reports Fiscal Second Quarter 2025 Financial Results218SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), today reported financial results for the second quarter ended Dec. 31, 2024, and provided a corporate update on its progress....
► Artikel lesen
10.02.iBio, Inc. - 10-Q, Quarterly Report-
10.02.iBio, Inc. - 8-K, Current Report-
31.01.iBio files for secondary offering3
31.01.iBio, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
10.01.iBio, Inc. - 8-K, Current Report1
07.01.iBio, Inc.: iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio199SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio Inc., announced today the development...
► Artikel lesen
03.01.iBio pens $29M biobucks deal with AstralBio for obesity med designed to preserve muscle mass1
02.01.Nano-Cap iBio Expands Obesity Program With New Antibody Using In-Licensed Platform1
02.01.iBio expands cardiometabolic and obesity program1
02.01.iBio, Inc.: iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio147SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced the expansion of its cardiometabolic and obesity...
► Artikel lesen
Seite:  Weiter >>
27 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1